Antibiotic resistance is rising to dangerously high levels in all parts of the world. New resistance mechanisms are emerging and spreading globally, threatening our ability to treat common infectious diseases. A growing list of infections are becoming harder, and sometimes impossible, to treat as antibiotics become less effective.

According to the World Health Organization, declining private investment and lack of innovation in the development of new antibiotics are undermining efforts to combat drug-resistant infections. Novel antibiotics are urgently needed.

At IRP Health, we are combining our formulations with existing human drugs to improve their efficacy in killing antibiotic resistance strains. We are using our library of compounds and leveraging Monash University’s capabilities to develop new solutions for the human health industry.